Enea's net sales rose 7% to SEK214m, beating Redeye Research Estimate (RRe) by 2%, with the network ...
Redeye comments on Lime’s Q1 report, with key figures missing our forecasts slightly.
Sales -3% vs. cons, adj. EBITA +21% vs. cons Announces growth initiatives & cost savings efforts Con...
Redeye updates its outlook on Nanologica, continuing to anticipate a considerable sales ramp-up in H...
Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, cur...
Redeye updates its estimates and valuation following Vitec releasing its Q1 2025 report.
Report out 8 May at 08:00 CEST Q1e: sales of SEK 52m +37% y-o-y, adj.
We raise '25e-'27e adj. EBITA by 10-1% on higher margins Low renegotiation risk 2025 and growth upsi...
Redeye is not entirely surprised to see that Absolent has experienced significant headwinds in Q1.
Hifab Group AB (”Hifab”, ”Koncernen” eller ”Bolaget”) publicerade den 23 april 2025 Bolagets delårsr...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 22 april 2025 att Bolaget, villkorat av bol...
Volvo delivered a mixed report, with EBIT 12% below Infront consensus.
Adj. EBITA +12% vs. cons, +39% vs. ABGSCe Better margins and guidance to improve conviction in margi...
Q1 report Tuesday, 29 April at 08:30 CET '25e EBITA up 2% 10-5x EBITA in '25e-'27e, 16-19% FCF yield...
Redeye comments on Truecaller ahead of its Q1 results, which are due on 8 May.
On April 22nd, Genetic Analysis AS (“Genetic Analysis” or the “Company”) announced that the Company ...
Two divestments and one acquisition announced Net effect: EBITA +4%, margins to increase from 9.
Q1e: revenues of DKK 320m, EBIT of DKK 11m, 3% margin Minor underlying revisions; major guidance rev...
Enersense will release new financial targets on 4 June 2025 at its CMD event.
Under de senaste sex månaderna har bolaget genomfört tre exits; Blackbuck, Gringo och Juspay, vilket...
